Altered Clearance of N-1 Methylnicotinamide Associated With the Use of Low Doses of Cyclosporine
-
Add time:08/29/2019 Source:sciencedirect.com
To improve the monitoring of patients on low doses of cyclosporine there is a need for new tests of tubular function. N-1 methylnicotinamide (NMN) is an endogenous organic cation that is secreted by the proximal tubule and its clearance can be measured. In 27 patients with psoriasis, serial measurements of NMN clearance, plasma aldosterone, plasma chloride, bicarbonate, and magnesium were compared with changes in the radionuclide measurement of glomerular filtration rate and renal blood flow before, during, and after a 3-month course of low-dose cyclosporine (<5 mg/kg/ d). N-1 methylnicotinamide clearance decreased significantly with cyclosporine only (2.5 mg/kg/d, n = 10, P < 0.01). Recovery of NMN clearance lagged behind that of glomerular filtration rate and renal blood flow. Serum magnesium decreased significantly on cyclosporine (2.5 mg/kg, n = 10, P < 0.01; 5 mg/kg, n = 9, P < 0.0001). In the whole group, plasma potassium increased significantly (n = 27, P < 0.02) and plasma aldosterone was inappropriately low. Low doses of cyclosporine in psoriasis cause a reduced clearance of NMN, hypomagnesemia, and a variable hyperchloremic acidosis. Nifedipine may alter these biochemical variables without necessarily improving renal hemodynamics. The delayed recovery of NMN clearance in comparison with renal haemodynamic measurements following cyclosporine therapy suggests that this noninvasive test of tubular function may be a marker of persisting cyclosporine nephrotoxicity and that it should be evaluated further.
We also recommend Trading Suppliers and Manufacturers of N-METHYLNICOTINAMIDE (cas 114-33-0). Pls Click Website Link as below: cas 114-33-0 suppliers
Prev:Crystal structures and spectroscopic behavior of monomeric, dimeric and polymeric copper(II) chloroacetate adducts with isonicotinamide, N-METHYLNICOTINAMIDE (cas 114-33-0) and N,N-diethylnicotinamide
Next:NeuroscienceFormation of N-METHYLNICOTINAMIDE (cas 114-33-0) in the brain from a dihydropyridine-type prodrug: Effect on brain choline) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- NeuroscienceFormation of N-METHYLNICOTINAMIDE (cas 114-33-0) in the brain from a dihydropyridine-type prodrug: Effect on brain choline08/30/2019
- Crystal structures and spectroscopic behavior of monomeric, dimeric and polymeric copper(II) chloroacetate adducts with isonicotinamide, N-METHYLNICOTINAMIDE (cas 114-33-0) and N,N-diethylnicotinamide08/28/2019
- Short communicationEc mechanisms: electrodimerization of N-METHYLNICOTINAMIDE (cas 114-33-0) on mercury electrode08/27/2019
- Original contributionThe metabolism of nicotinamide in human liver cirrhosis: a study on N-METHYLNICOTINAMIDE (cas 114-33-0) and 2-pyridone-5-carboxamide production08/26/2019
- Nicotinamide N-methyltransferase (NNMT) and 1-methylnicotinamide (MNA) in experimental hepatitis induced by concanavalin A in the mouse08/25/2019
- Activation of nicotinamide N-methyltrasferase and increased formation of 1-methylnicotinamide (MNA) in atherosclerosis08/24/2019
- Thermodynamic study of nicotinamide, N-METHYLNICOTINAMIDE (cas 114-33-0) and N,N-dimethylnicotinamide: Vapour pressures, phase diagrams, and hydrogen bonds08/23/2019
- Study of copper(II) thiophenecarboxylate complexes with N-METHYLNICOTINAMIDE (cas 114-33-0)08/22/2019
- Original articleCardioprotective effect of N-METHYLNICOTINAMIDE (cas 114-33-0) salt of pyruvate in experimental model of cardiac hypoxia08/21/2019


